| Thrombin and antithrombotic therapy in interventional cardiology. | |
| | |
MedLine Citation:
|
PMID: 8061538 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite developments in percutaneous transluminal coronary angioplasty, the success of this treatment method remains clouded by early and late reocclusion. Increased experience, advances in technology, and the introduction of adjunctive devices have contributed to a higher procedural success rate (90% to 95%) and to a lower complication rate (4% to 5%), in spite of the expanded indications for angioplasty. Late renarrowing of the treated coronary artery, in combination with recurrence of angina pectoris, occurs in 15% to 40% of angioplasty patients. Several multicenter randomized trials of pharmaceutical agents have been conducted or are in progress, in an effort to diminish the rate of late reocclusion. No major breakthrough has been reported, although a clear progression has been made in the understanding of the restenosis phenomenon. It is evident that thrombin plays a detrimental role in the vascular wall injury resulting from angioplasty procedures. Current pharmacologic research concentrates on direct inhibition of prothrombin conversion and thrombus formation. Animal experimental work in this field is encouraging, and the results of clinical trials will elucidate important questions about the safety, efficacy, and immuno-allergic potential of modern antithrombotic medication. |
| | |
Authors:
|
J P Herrman; P W Serruys |
Related Documents
:
|
10334418 - Abciximab in the treatment of acute myocardial infarction eligible for primary percutan... 3156288 - Percutaneous transluminal coronary angioplasty: the early dunedin experience. 16521638 - Transradial primary angioplasty and stenting in indian patients with acute myocardial i... 10406068 - Experiences with primary angioplasty without on site-cardiac surgery. 7743618 - Dispersion of 'refractoriness' in noninfarcted myocardium of patients with ventricular ... 22477398 - A modern cause of an old disease. constrictive pericarditis after percutaneous coronary... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital Volume: 21 ISSN: 0730-2347 ISO Abbreviation: Tex Heart Inst J Publication Date: 1994 |
Date Detail:
|
Created Date: 1994-09-22 Completed Date: 1994-09-22 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 8214622 Medline TA: Tex Heart Inst J Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 138-47 Citation Subset: IM |
Affiliation:
|
Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary* Animals Antithrombins / therapeutic use* Coronary Disease / therapy* Fibrinolytic Agents / therapeutic use* Heparin / therapeutic use Hirudin Therapy Humans Pipecolic Acids / therapeutic use Platelet Membrane Glycoproteins / antagonists & inhibitors Recurrence Thrombin* |
| Chemical | |
Reg. No./Substance:
|
0/Antithrombins; 0/Fibrinolytic Agents; 0/Pipecolic Acids; 0/Platelet Membrane Glycoproteins; 74863-84-6/argatroban; 9005-49-6/Heparin; EC 3.4.21.5/Thrombin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transesophageal electrocardiography and adenosine in the diagnosis of wide complex tachycardia.
Next Document: Primary coronary angioplasty in patients with acute myocardial infarction.